Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash & Equivalents (2016 - 2025)

Cytosorbents' Cash & Equivalents history spans 15 years, with the latest figure at $6.2 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $6.2 million for Q4 2025, up 90.52% from a year ago — trailing twelve months through Dec 2025 was $6.2 million (up 90.52% YoY), and the annual figure for FY2025 was $6.2 million, up 90.52%.
  • Cash & Equivalents for Q4 2025 was $6.2 million at Cytosorbents, down from $7.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $68.5 million in Q1 2021 to a low of $1.7 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $12.9 million (2023), against an average of $23.5 million.
  • The sharpest move saw Cash & Equivalents tumbled 94.36% in 2023, then surged 397.57% in 2024.
  • Year by year, Cash & Equivalents stood at $52.1 million in 2021, then plummeted by 57.53% to $22.1 million in 2022, then tumbled by 36.19% to $14.1 million in 2023, then tumbled by 76.79% to $3.3 million in 2024, then skyrocketed by 90.52% to $6.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $6.2 million, $7.5 million, and $10.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.